Abstract Body

Background: Concerns with current and/or long-term side effects or dosing complexity of antiretroviral (ARV) regimen may prompt patients to request ARV switches. We report the Week (W) 48 results of a prospective, randomized, open-label, ongoing Phase 3b trial of a regimen switch to the single-tablet regimen (STR) elvitegravir/cobicistat/emtricitabine/tenofovir DF (E/C/F/TDF) from non-nucleoside reverse transcriptase inhibitor (NNRTI) + emtricitabine/ tenofovir DF (FTC/TDF) regimens in virologically-suppressed HIV-1 subjects. Methodology: Subjects suppressed on NNRTI + FTC/TDF regimens for ≥ 6 months were randomized (2:1) to switch to E/C/F/TDF or remain on their baseline NNRTI regimen (i.e. NNRTI). Eligibility criteria included CrCl ≥ 70 mL/min, no documented resistance to FTC and TDF, exposure to no more than 2 prior ARV regimens, and no history of virologic failure. The primary endpoint was the proportion of subjects who maintained HIV-1 RNA < 50 c/mL at W48 by FDA snapshot algorithm (12% noninferiority margin). Results: A total of 434 subjects (93% male, 22% non-white, 22% age ≥ 50 years) were randomized and treated (291 E/C/F/TDF; 143 NNRTI). At randomization, 78% of subjects were on an efavirenz (EFV)-based regimen (74% on STR EFV/FTC/TDF); median years since first ARV use was 3; and 31% enrolled in the study due to concern with current or long-term side effects of their ARVs. Baseline characteristics were similar between the two groups. E/C/F/TDF was noninferior to NNRTI regimens, as 93% and 88% respectively maintained HIV-1 RNA < 50 c/mL at W48 (difference 5.3%, 95% CI -0.5%, +12.0%). Virologic failure rates were 1% with no emergent resistance detected in either group. The safety and tolerability profiles of E/C/F/ TDF were consistent with reports from previous studies. Grade 2-4 drug-related adverse events (AEs) occurred in 5.5% E/C/F/TDF and 1.4% NNRTI. AEs leading to discontinuation were low (2.1% E/C/F/TDF vs 0.7% NNRTI). Median changes in CrCl (mL/min) at W48 were, as expected, -11.6 and -0.2 respectively. Small decreases from baseline in total, LDL, and HDL cholesterols were experienced by those switching from EFV-based regimens. Decreases from baseline at W48 in rates of neuropsychiatric symptoms, e.g. vivid dreams (-15%, p <0.001), dizziness (-11%, p <0.001), anxiety (-9%, p =0.008), and insomnia (-10%, p =0.004), were reported after switching to E/C/F/TDF [HIV Symptom Index]. HIV Treatment Satisfaction scores were higher for subjects who switched to E/C/F/TDF (p <0.001) [HIV Treatment Satisfaction Questionnaire]. Conclusions: Switching to E/C/F/TDF from NNRTI + FTC/TDF regimens was associated with high rates of virologic suppression, no resistance development, and favorable tolerability with improved treatment satisfaction.